NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Lyka Labs Limited (NSE: LYKALABS)
LYKALABS Technical Analysis
1
As on 1st Dec 2023 LYKALABS SHARE Price closed @ 126.60 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
LYKALABSSHARE Price
Open | 127.15 | Change | Price | % |
High | 135.75 | 1 Day | N/A | N/A |
Low | 126.20 | 1 Week | 0.00 | 0.00 |
Close | 126.60 | 1 Month | 0.00 | 0.00 |
Volume | 127549 | 1 Year | 0.00 | 0.00 |
52 Week High 0.00 | 52 Week Low 0.00 |
NSE INDIA Most Active Stocks
IDEA | 13.25 | 1.53% |
YESBANK | 19.30 | -0.26% |
TV18BRDCST | 48.00 | 11.37% |
PNB | 80.70 | 3.99% |
RPOWER | 20.85 | -1.42% |
NHPC | 56.40 | 3.68% |
JPPOWER | 12.85 | -1.91% |
SUZLON | 39.40 | -3.31% |
ZOMATO | 116.30 | -1.90% |
GAIL | 136.05 | 3.15% |
NSE INDIA Top Gainers Stocks
BIL | 284.85 | 19.23% |
BIL | 284.85 | 19.23% |
BIL | 284.85 | 19.23% |
BIL | 284.85 | 19.23% |
BIL | 284.85 | 19.23% |
BIL | 284.85 | 19.23% |
BIL | 284.85 | 19.23% |
BIL | 284.85 | 19.23% |
SHALPAINTS | 198.70 | 17.85% |
DATAMATICS | 740.05 | 16.78% |
NSE INDIA Top Losers Stocks
WHIRLPOOL | 1416.00 | -9.88% |
NIACL | 231.25 | -9.38% |
GODHA | 0.50 | -9.09% |
SMLISUZU | 1410.15 | -7.10% |
TVSSRICHAK | 4552.35 | -5.58% |
LCCINFOTEC | 1.80 | -5.26% |
ORIENTCEM | 246.85 | -5.08% |
COMPUSOFT | 39.40 | -4.95% |
GANESHBE | 162.05 | -4.79% |
ALPSINDUS | 2.00 | -4.76% |
LYKALABS Daily Charts |
LYKALABS Intraday Charts |
Whats New @ Bazaartrend |
LYKALABS Free Analysis |
|
LYKALABS Important Levels Intraday
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
LYKALABS Target December 2023
4th UP Target | 0 |
3rd UP Target | 0 |
2nd UP Target | 0 |
1st UP Target | 0 |
1st DOWN Target | 0 |
2nd DOWN Target | 0 |
3rd DOWN Target | 0 |
4th DOWN Target | 0 |
LYKALABS Weekly Target
4th UP Target | 0.00 |
3rd UP Target | 0.00 |
2nd UP Target | 0.00 |
1st UP Target | 0.00 |
1st DOWN Target | 0.00 |
2nd DOWN Target | 0.00 |
3rd DOWN Target | 0.00 |
4th DOWN Target | 0.00 |
LYKALABS Target2023
4th UP Target | 0 |
3rd UP Target | 0 |
2nd UP Target | 0 |
1st UP Target | 0 |
1st DOWN Target | 0 |
2nd DOWN Target | 0 |
3rd DOWN Target | 0 |
4th DOWN Target | 0 |
Lyka Labs Limited ( NSE INDIA Symbol : LYKALABS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
LYKALABS Synopsis Technicals View
50 Day EMA |
Close is Above EMA 50 (Short Term) |
Bullish | |
100 Day EMA | Close is Above EMA 100 (Mid Term) | Bullish | |
200 Day EMA | Close is Above EMA 200 (Long Term) | Bullish | |
MACD (12 26 9) | MACD Line is Less Then SIGNAL Line | Bearish | |
RSI (14) | RSI is Below 30 | Over Sold | |
MFI (14) | MFI is 22.98 | Sideways | |
CCI (20) | CCI is Below -100 | Over Sold | |
WILLIAM %R (14) | William %R is Below -80 | Over Sold | |
ADX (14) | ADX is Above 20 & +DI is Below -DI | Down Trend | |
PSAR | Stoploss For Long Buy | 16.18 | |
10 Day Avg Volume | Traded 247.61 % More then 10 Day Average Volume |
LYKALABS Other Details
Segment | EQ | |
Market Capital | 2685383936.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
LYKALABS Address
![]() |
LYKALABS Latest News
LYKALABS Business Profile
Lyka Labs Limited engages in the manufacturing and sale of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. It manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. The company also provides contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, BA/BE clinical study data, etc. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. Lyka Labs Limited offers its products in various formulations, including injections, creams, ointments, foams, gels, and lotions. Further, the company exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India. Address: Spencer Building, Mumbai, India, 400036
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service